Scientists at the Department of Cancer Research (DoCR) at the Luxembourg Institute of Health (LIH) have revealed the ground-breaking therapeutic potential of the compound FL3 in inhibiting oncogene translation and rewiring cancer cell metabolism, offering new hope for patients with chronic lymphocytic leukaemia (CLL), a prevalent form of cancer characterised by the overproduction and accumulation of dysfunctional B lymphocytes in various parts of the body. Click to read more.
Cutting-edge research at the Luxembourg Institute of Health reveals the ground-breaking therapeutic potential of the compound FL3 in inhibiting oncogene translation and rewiring cancer cell metabolism, opening up new therapeutic opportunities for leukemia patients.
Luxembourg Scientists Make Progress in Leukaemia Research chronicle.lu - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from chronicle.lu Daily Mail and Mail on Sunday newspapers.